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Abstract: The Global Plan towards the elimination of new HIV
infections among children by 2015 and keeping their mothers alive
(Global Plan) has ensured that more infants in high-HIV burden
countries survive childhood HIV-free. Although equal numbers of boy
and girl children have survived to age 10, a gender divergence starts to
emerge as they enter adolescence. Up to 3 times as many young
women aged 15–24 years in eastern and southern Africa are living with
HIV compared with their male peers. Further, more adolescent girls
and young women are sick and/or dying from AIDS-related or
HIV-related complications during pregnancy and in the postpartum
period, underscoring the importance of strengthening HIV treatment
and prevention services for this group. Failure to prevent HIV in
adolescent girls and young women and keep them alive will reverse the
infant HIV prevention and survival gains made under the Global Plan.
The promising global declines in HIV infection in young women need
to be strengthened to realize the goals of an AIDS-free generation. The
DREAMS initiative of the United States President’s Emergency Plan
for AIDS Relief (PEPFAR), which specifically addresses adolescent
girls and young women at highest risk of HIV acquisition, brings new
hope for meeting the prevention and care needs of this important and
vulnerable population through political commitment, leadership,
financial and human resource investments, advocacy efforts, and
a focus on the highest priority settings. Importantly, to achieve the
goal of keeping mothers alive, we have to place more emphasis on
access to sexual and reproductive health services that (1) include HIV
prevention and treatment services for adolescent girls and young
women; (2) increase male/paternal responsibility in mother and infant
health; and (3) ensure a supportive social environment that enables
young women to grow up into young adults who are free to graduate
from high school and plan their pregnancies, ultimately entering
adulthood safe, healthy, and free from HIV.
Key Words: young women, adolescents, HIV, prevention, DREAMS,
Global Plan
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INTRODUCTION
The Global Plan towards eliminating HIV infections
among children by 2015 and keeping their mothers alive
(Global Plan) revolved around 4 prongs: (1) prevent HIV
among women of reproductive age; (2) prevent unintended
pregnancies among women living with HIV; (3) prevent
HIV transmission through the use of antiretroviral medicines
during pregnancy and breastfeeding; and (4) provide treat-
ment, care, and support for mothers living with HIV, their
children, partners, and families.1 Since the launch of the
Global Plan, coverage of services to prevent mother-to-child
transmission of HIV increased dramatically, reaching 77%
in 2015. As a result, new HIV infections among children
aged 0–14 years have declined by 51% since 2010. In
addition, the number of children aged 0–14 years on
antiretroviral therapy globally has increased from 452,000
children in 2010 to 910,000 children by 2016, reducing
AIDS-related deaths among children by 44%.2 The sub-
stantial reductions in new HIV infections among children
and huge declines in AIDS-related deaths among infants
were because of the early initiation of antiretroviral therapy
for infants infected with HIV based on compelling scientific
evidence and the implementation of prong 3 and prong 4. In
contrast, progress made in keeping mothers alive has been
limited primarily because of challenges in preventing HIV
infection in women and operational challenges in imple-
menting prongs 1 and 2 (and facets of prong 4), most notably
in relation to treatment, care, and support of mothers living
with HIV, their partners, and families. These limitations
have been most pronounced in the high HIV burden settings
of eastern and southern Africa.
The rationale for prongs 1 and 2 is based on scientific
evidence and is an effective strategy for indirectly preventing
infants from acquiring HIV.1 It also is an important oppor-
tunity to engage and link women to essential HIV prevention,
treatment, care, and sexual and reproductive health services.
However, adolescent girls and young women—particularly
unmarried pregnant teenagers and/or survivors of sexual
abuse—are less likely than older women to use the appropri-
ate and available prevention or treatment services.
Given that entry into prevention of mother-to-child
transmission (PMTCT) programs is usually through antenatal
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services, adolescent girls and young women who do not
access antenatal care services also will not access PMTCT
services. Furthermore, a study in KwaZulu-Natal among
19,093 women found that even when adolescent girls do
access antenatal care during pregnancy, they do not always
receive the appropriate HIV treatment and prevention serv-
ices. There was also an apparent age disparity, where the HIV
transmission rate at 4–8 weeks of age was significantly higher
among infants of adolescent mothers than among infants of
older mothers (OR: 1.7, 95% CI: 1.2 to 2.4).3
Notably, there has been insufficient progress in HIV
prevention options for adolescent girls. As we move into the
post-Global Plan era, particular attention needs to turn to 3
groups of adolescents: (1) children infected at birth or in
infancy who are now transitioning to adolescence; (2) those
who are HIV-negative but at high risk of acquiring HIV
because of social circumstances (eg, AIDS orphans and
children of child-headed households); and (3) other adoles-
cents who engage in high-risk behavior.
In this study, we draw attention to the complexities
associated with adolescence, describe factors impacting the
risk of acquiring HIV among adolescents, and discuss the
progress made both in preventing HIV in adolescent girls and
young women—with specific reflections on its implications
for fully realizing the goal of eliminating HIV among infants
and keeping their mothers alive—and in sustaining the gains
and progress made to date.
EPIDEMIOLOGY OF HIV IN ADOLESCENT GIRLS
AND YOUNG WOMEN
Although global HIV trends indicate a decline in the
number of new cases of HIV infection (from 3.4 million in 2001
to 2.1 million in 2015), these trends mask the continued spread
of HIV in certain regions, populations, and age groups.4 Of the
10 countries that contribute two-thirds of all HIV infections
globally, 7 are in eastern and southern Africa.5 In these regions,
women account for 59% of all people living with HIV, and
adolescent girls and young women aged 15–24 years are
particularly vulnerable (Table 1). Of the estimated 3.9 million
young people aged 15–24 years living with HIV in 2014, 2.3
million (58%) were young women. Throughout sub-Saharan
Africa, HIV prevalence among adolescent girls and young
women exceeds that of their male peers, with HIV prevalence
up to 6 times higher in South Africa (Box 1).18 Although the
cause of this vulnerability has not been fully elucidated, it is
compounded by structural, social, and biological factors.
BOX 1. Focus on KwaZulu-Natal, South Africa
South Africa accounts for 18% of the global burden
of HIV infection, with about 1000 new infections each
day.6 The province of KwaZulu-Natal is at the epicenter of
the pandemic: 4 of its 11 districts have HIV prevalence
among pregnant women of greater than 40%, and the
remaining 7 districts having an HIV prevalence between
35.9% and 39.9%.7
IMPORTANCE OF AGE STRATIFICATION
HIV surveillance in pregnant women and repeated
cross-sectional studies conducted over the past decade in
the high burden KwaZulu-Natal subdistrict of uMgungund-
lovu show that, although HIV prevalence has remained
stable over recent years, incidence rates remain unaccept-
ably high in women below 30 years of age. In the
uMgungundlovu subdistrict, by age 16, 1 in every 10
women coming to antenatal services are already infected
with HIV. This increases to 1 in 3 by age 20 and 1 in 2 by
age 24 (see table below).8 A survey conducted among high
school students in this subdistrict found that HIV preva-
lence in girls was 6-fold higher than in boys. An age-
specific breakdown from this survey indicates that by age
18, 7.1% of girls are infected with HIV; by age 25, this
increases to 24%.9 Several other cohort and longitudinal
studies in South Africa show high HIV incidence rates
among young women.10–16 High HIV incidence rates also
have been observed in postpartum women in periurban
communities in KwaZulu-Natal.17
HIV in Pregnant Women in the uMgungundlovu
Subdistrict, KwaZulu-Natal, South Africa (2001–2013)
TABLE 1. HIV Prevalence in Adults and Young Women in















Kenya 5.9 (4.9 to 7.0) 4.0 (3.1 to 5.1) 2.3 (1.6 to 3.2)
Lesotho 22.7 (20.8 to 24.3) 9.1 (7.9 to 11.2) 5.1 (3.4 to 7.6)
Malawi 9.1 (8.4 to 9.9) 3.2 (2.6 to 4.0) 1.8 (1.4 to 2.4)
Mozambique 10.5 (8.3 to 13.3) 4.0 (2.9 to 5.6) 2.3 (1.3 to 3.9)
South Africa 19.2 (18.4 to 20.0) 11.6 (10.1 to 14.1) 4.0 (2.8 to 5.8)
Swaziland 28.8 (26.7 to 30.5) 16.7 (14.7 to 20.0) 7.3 (5.0 to 10.7)
Uganda 7.1 (6.6 to 7.7) 3.2 (2.7 to 4.0) 1.9 (1.3 to 2.7)
Tanzania 4.7 (4.2 to 5.3) 1.6 (1.4 to 2.0) 1.0 (0.8 to 1.5)
Zambia 12.9 (12.3 to 13.4) 5.0 (4.4 to 6.0) 3.1 (2.3 to 4.4)
Zimbabwe 14.7 (13.3 to 16.0) 5.9 (5.0 to 7.3) 3.8 (2.7 to 5.2)
UNAIDS AIDSInfo. Available at: http://aidsinfo.unaids.org. Adaptations are
themselves works protected by copyright. So in order to publish this adaptation,
authorization must be obtained both from the owner of the copyright in the original work
and from the owner of copyright in the translation or adaptation.







Source: Adapted from Kharsany AB, Mlotshwa M, Frohlich JA, et al. HIV
prevalence among high school learners—opportunities for schools-based HIV testing
programmes and sexual reproductive health services. BMC Public Health. 2012;12:231.
Adaptations are themselves works protected by copyright. So in order to publish this
adaptation, authorization must be obtained both from the owner of the copyright in the
original work and from the owner of copyright in the translation or adaptation.
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FACTORS CONTRIBUTING TO THE INCREASED
VULNERABILITY OF YOUNG WOMEN IN
ACQUIRING HIV
Adolescence and the Complexities of the
Transition to Adulthood
Adolescence is a development phase characterized by
increased risk-taking, instant gratification, and greater peer
influence in decision-making. During this time, new bound-
aries are explored, and parental and societal rules and norms
that were unchallenged during childhood are reexamined,
questioned, and/or defied in preparation for adulthood and
autonomy.19 The period of adolescence is associated with
complex emotional, physical, and cognitive changes.20
Vulnerabilities in youth often are exacerbated by the
interaction of the effects of social disparities and the realities
of everyday life. Sexual risk-taking in settings where HIV
infection is rare has a different impact and implication when
compared to communities with a high prevalence of HIV,
where the probability of acquiring HIV is substantially
higher. In addition, where social disparities exist—for
example in relation to access to health services—the out-
comes from exposure to HIV or being infected also are
different.21,22
Although adolescents comprise about 25% of the
global population, sub-Saharan Africa is the only region in
the world where more than one-third of the population is
between 10 and 24 years of age, creating what is referred to
as the “youth bulge” in the population pyramid.23 The
implications of a high burden of HIV in adolescent girls
and young women, together with increased HIV-related
morbidity and mortality rates, have profound social im-
plications in this setting given the central and critical social
and economic role of women in society. This situation is
exacerbated by an emerging trend of convergence between
communicable and noncommunicable diseases.22 Con-
certed effort and investment are needed to ensure that
equal numbers of young boys and girls in sub-Saharan
Africa are able to enter adulthood healthy and realize their
full potential. The age–sex disparities in HIV infection and
survival being experienced, notably in eastern and southern
Africa, pose a significant threat to social cohesion and
economic development in the region, both immediately and
in the long term, and they require urgent attention.
The “youth bulge,” in combination with the delayed
rollout of treatment with antiretroviral medicines that led
to the loss of several hundreds of thousands of parents
from AIDS-related causes, contributed to a significant
increase in child-headed households in sub-Saharan Afri-
ca.24 The implications of this situation are manifold, and
they include poverty, concerns about livelihood, preco-
cious familial responsibilities, and isolation and margin-
alization because of social stigma and discrimination. All
of these implications impact the sexual decisions of
adolescent girls and young women differently compared
with boys. In some instances, this can lead to sex for
survival or increased exposure to gender-based violence,
which in turn has consequences that include sexually
transmitted infections (STIs) and pregnancy.25 Young
women in child-headed and poor households are especially
vulnerable to acquiring HIV.
Sexual Coupling Patterns
In sub-Saharan Africa, adolescent girls and young
women tend to acquire HIV infection at a much earlier age
than their male peers.26,27 This age–sex disparity in infection
rates is a consequence of young girls partnering with men
who are about 5–10 years older than them, and who may have
recently acquired HIV or who are already living with HIV but
are not on treatment with antiretroviral medicines.28–31
Adolescent girls and young women engage in sexual relation-
ships with older men for multiple reasons. Although some
relationships are based on love or sexual curiosity, in some
instances, particularly for those from impoverished back-
grounds, young women may engage in transactional sex and
form relationships with older men for financial and social
security.32–34 Understanding the drivers of this partnering
pattern and learning more about these male partners is critical
for addressing the prevention needs of adolescent girls and
young women.35
In addition to unknowingly choosing a sexual partner
who may be already infected with HIV, early sexual debut,
teen pregnancies, early school dropout, and sexual violence
also increase the vulnerability of adolescent girls and young
women to acquiring HIV infection and maintain them in
vicious cycles of poverty and dependency.
Young people, on average, have their first sexual
encounters during their teenage years: in sub-Saharan Africa,
about 60% of young women are sexually active by the time
they reach the age of 18 (Table 2). In this region, although
unprotected sex between adolescent peers can result in
pregnancy, HIV is rare. In contrast, sex with an older man
is more likely to result in HIV acquisition and pregnancy.
Data from South Africa show that women who have a young
age of sexual debut are more likely to have an older first
sexual partner and are more likely to have experienced sexual
coercion.36 Early sexual debut has also been associated with
subsequent sexual risk-taking, such as having multiple
partners.28,37,38 Young people also are less likely to be
experienced in discussing safe sex. Gender-power imbalances
that exist in age-disparate relationships result in challenges for
younger women in negotiating safer sex practices, including
consistent condom use.
Adolescent girls and young women who engage in
unprotected sex can become pregnant, which has the potential
to adversely impact a young woman’s opportunities for
education, as it has been found that the majority of pregnant
teenagers rarely return to school after childbirth.39 The
vulnerability of teenage girls who drop out of school is
further perpetuated as they transition to adulthood because of
the limited economic options available or accessible to those
who do not complete high school.
In addition to the economic disadvantages, pregnant
adolescent girls below the age of 15 face a particularly high
risk of maternal mortality. According to the United Nations
Population Fund (UNFPA), girls below the age of 15 are 5
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times as likely—and those aged 15–19 years are 2 times as
likely—to die from complications of childbirth than women
in their 20 seconds. A systematic analysis of population
health data shows that complications in pregnancy and
childbirth are one of the leading causes of death among
adolescent girls in developing countries.40 Young women
also are more likely than older women to seek abortions,
particularly if the pregnancy is unintended. The estimated
unintended pregnancy rate in Africa in 2008 was 86 per 1000
women, one-third of which were terminated through abor-
tions, often under unsafe conditions.41 Globally, unsafe
abortions are estimated to cause 70,000 maternal deaths each
year.41 About 13% of the unsafe abortions that occur annually
in the developing world (2.5 million of the approximately 19
million) are among adolescents.41
Provision of family planning and the prevention of
unintended pregnancies is important for all women but
especially for adolescent girls, who are at greater risk for
pregnancy-related complications (such as obstetric hemor-
rhage and hypertension). Eliminating the unmet need for
family planning among all women (including women living
with HIV) is one prong of the Global Plan; however, the most
recent population-based surveys show that most countries in
eastern and southern Africa do not meet the need for family
planning among at least 25% of all sexually active unmarried
women (Table 2).
There is a bidirectional relationship between gender-
based violence and HIV infection. Women who have been
subjected to intimate partner violence or gender-based
violence face an increased risk for acquiring
HIV30,31,42,43 because they often adopt risky behaviors.44
A study in South Africa among 1099 women found an HIV
incidence rate of 9.6 per 100 women-years of follow-up
among women who reported more than 1 episode of
intimate partner violence; this was compared with 5.2 per
100 women-years of follow-up among those who reported
1 or no episode (IRR: 1.51, 1.04–2.21, P = 0.032).42 In
Rwanda, women who were HIV-positive were more likely
to report a history of violent relationships (46% versus
29%) and sexual coercion by their partners (43% versus
29%) than those who were HIV-negative.45 A Tanzanian
study found that women younger than 30 who were living
with HIV were 10 times more likely to report at least 1
event of physical or sexual violence than HIV-negative
women of similar age (OR: 9.99; 95% CI: 2.67 to 37.37).46
Biological Risk Factors
The high HIV incidence rates observed among adoles-
cent girls and young women in sub-Saharan Africa suggest
that factors beyond behavior may be contributing to the
heightened vulnerability in this group. Women are biologi-
cally more vulnerable to HIV and are, on average, twice as
likely as men to become infected after a single sexual
encounter.47 The biological mechanisms that make women
more vulnerable than men in acquiring HIV are in the process
of being established, although one contributing factor could
be that the large exposed mucosal surface of the vagina may
facilitate HIV acquisition. Furthermore, the high levels of
immune cell activation (which is the viral target for infection)
in the female genital tract and the increased expression of
HIV coreceptors in cervical cells (compared with foreskin
cells) may explain why women have a higher per-act risk of
HIV acquisition then men.48,49 Genital trauma experienced as
a result of forced or unwanted sexual intercourse can facilitate
HIV transmission.50
Inflammation in the female genital tract also may be
an important risk factor: analysis of female genital tract
samples from a recent microbicide trial that assessed
tenofovir gel for HIV prevention showed that genital
inflammation, defined by combinations of elevated proin-
flammatory cytokines, was associated with a 3-fold
TABLE 2. Most Recent Available Population-Based Data on Sexual Behavior, Contraceptive Use, Experiences of Sexual Violence,
Pregnancy, Marital Status, and Education in Women From Selected Countries in Eastern and Southern Africa
Country Year































Kenya 2014 42.6 12.8 18.2 14.1 6.5 14.7 27.4 42.7
Lesotho 2009 35.9 15.8 18.3 — — 15.8 25.8 52.2
Malawi 2010 35.4 20.0 17.4 25.3 17.8 20.1 51.6 20
Mozambique 2011 12.3 20.8 16.1 12.3 9.3 29.3 43.9 17.1
South Africa 1998 50.1 12.1 17.8 — — 13.2 12.7 68.3
Swaziland 2006–07 37.9 16.5 18.2 — — 18.5 14.5 59.3
Tanzania 2010 28.8 17.7 17.4 20.3 13.2 17.2 39.4 16.2
Uganda 2011 23.6 24.5 17.5 30.6 19.2 18.1 48.6 27.7
Zambia 2013–14 35.1 16.7 17.7 17.4 8.2 23.3 41.8 44.8
Zimbabwe 2010–11 41.3 10.3 18.9 27.2 18.0 18.6 30.7 69.7
—, data not available.
The DHS Program. Available at: http://www.dhsprogram.com/Data/. Adaptations are themselves works protected by copyright. So in order to publish this adaptation, authorization
must be obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation.
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increase in the risk of HIV acquisition.51 The cause of this
inflammation is still unclear, and a better understanding of
the immunological basis of correlates of HIV transmission
in young women could yield useful clues to future HIV
prevention technologies and strategies.
Sexual debut also marks the initial exposure to a number
of sexually transmitted pathogens, including viruses such as
herpes simplex type-2 virus (HSV-2) and human papilloma-
virus (HPV), which have been associated with a 2-fold to 3-
fold increased risk of HIV transmission.52,53
The use of injectable hormonal contraception, particu-
larly depot-medroxyprogesterone acetate (DMPA), has
recently emerged as a potential mediator of HIV risk.
Although uncertainty remains about the association between
DMPA use and HIV risk in young women, DMPA remains
the most common choice of contraceptive in sub-Saharan
Africa. A meta-analysis that included 18 studies has sug-
gested that DMPA is associated with a moderate increase in
the risk of HIV acquisition.54 Although we wait for definitive
evidence of the association between DMPA and HIV risk
from an ongoing randomized controlled trial, women at high
risk of HIV using this method should be strongly advised to
also use condoms (male or female). The United States
Agency for International Development (USAID) has devel-
oped a strategic communication framework to guide country-
level activities to communicate the risks and benefits of
hormonal contraception among women at risk of, or living
with, HIV through the use of an easy-to-understand and
comprehensive format.55
Limitations of Current HIV Prevention
Options for Adolescent Girls and
Young Women
Although the number of HIV prevention options has
expanded, the number of strategies that empower women to
directly control their risk of HIV remains quite limited.
Numerous social and behavioral change interventions aimed
at preventing HIV—including peer education, mass media
communication, school-based sex education programs, and
behavioral counseling—have been assessed.56 Although
many of the studies result in slight improvements in
behavioral outcomes (increased HIV knowledge, increased
condom use, and a reduction in high-risk sexual behavior),
few show a significant impact on biological outcomes (such
as HIV incidence).
Campaigns promoting abstinence, mutual faithfulness,
condom use, and circumcision also have had a limited impact
on HIV incidence in young women. A systematic review that
included 13 trials and 15,940 youths found that abstinence
programs had no impact reducing unprotected vaginal sex,
reducing the number of partners, increasing condom use, or
delaying sexual initiation.57 Data from South Africa show that
rates of reported early sexual debut (ie, before the age of 15
years) have remained almost stable at 10% since 2002.27
Male and female condoms are an essential component
of HIV prevention programs. They are inexpensive and, when
used correctly and consistently, provide protection against
acquisition and transmission of HIV and a variety of other
STIs, and against pregnancy.58 However, gender inequality
and the threat of intimate partner violence also limit
a women’s ability to successfully negotiate condom use with
male partners, to insist on mutual monogamy, or to convince
partners to have an HIV test. Furthermore, medical male
circumcision, which is widely promoted for HIV prevention
in high HIV burden countries, primarily benefits the male
partner. Any protective benefits for women are likely to be
realized only 5 or more years later.59
Progress on Women-Initiated HIV
Prevention Technologies
The development of HIV prevention strategies that can
be directly controlled by women remains an important global
goal. One promising HIV prevention option that could
directly empower women to limit their HIV risk is the topical
(microbicides) or oral use of antiretroviral-containing agents
by HIV-uninfected persons, also referred to as preexposure
prophylaxis (PrEP).
Although no topical microbicides are yet licensed or
available, results from the CAPRISA 004 tenofovir gel trial
provided proof-of-concept that topical antiretroviral micro-
bicides, when used before and after sex, can reduce sexual
transmission of HIV and HSV-2 in women.16 However, the 2
confirmatory trials—the FACTS 001 trial of pericoital gel use
and the VOICE trial of daily tenofovir gel—were unable to
confirm the CAPRISA 004 trial results.60,61 This may have
been primarily because of suboptimal adherence: measure-
ment of tenofovir concentrations in blood found that only
25% of women assigned to the tenofovir gel group in the
VOICE trial and about half of the women in the FACTS 001
trial had detectable drug levels, meaning that most women in
the trials did not take the study drug as prescribed.60,61
Given the adherence challenges, the field has shifted its
focus to developing products that are long-acting and less
user-dependent. Data from 2 efficacy trials evaluating the
long-acting antiretroviral dapivirine intravaginal ring are
encouraging and show that high levels of adherence are
achievable (82% in ASPIRE and 73% in the IPM Ring
study).62,63 The monthly dapivirine vaginal ring reduced HIV
incidence rates by 27% in the MTN ASPIRE trial and 31% in
the IPM Ring study.62,63 However, adherence (based on drug
levels in plasma samples) was shown to be 2-fold to 4-fold
lower in young women (,21 years) than older women; as
a result, no protection was observed in young women.62 An
open-label, posttrial access study is planned to further
investigate this finding. If licensed, the product could become
available as an HIV prevention option for women in about 4–
5 years.
New formulations and delivery devices, such as PrEP
injections lasting 2–3 months and implants lasting 6–12
months, are being evaluated. Furthermore, passive immuni-
zation studies using broadly neutralizing antibodies for HIV
prevention are in development. Successful outcome of these
trials could expand the prevention options for women and
pave the way for multipurpose technologies that are being
developed to simultaneously address HIV prevention, fertility
control, and STI prevention for women.64
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Several randomized double-blind, placebo-controlled
trials in a range of settings and populations have demon-
strated that oral PrEP, when used correctly and consistently,
can prevent sexual transmission of HIV.65–70 Oral PrEP is an
important HIV prevention option for women, and it is one of
the few strategies that a woman can directly control. Oral
PrEP is therefore a potentially promising strategy for reducing
HIV among adolescent girls and young women. However, the
evidence of efficacy in women is inconsistent.61,71 Although
2 trials (Partners PrEP68 and Botswana TDF269) have
demonstrated a protective effect of oral PrEP ranging from
66% to 75% in women, 2 other trials (the FEMPrEP and
VOICE trials) showed no protective effect of PrEP in this
group.61,71 An analysis of drug concentrations revealed that
less than 30% of the women in these trials were able to adhere
to the prescribed intervention.71 The ADAPT Study (HPTN
067), conducted among women in Cape Town, has shown
that young, single black women in South Africa can take and
adhere to a daily regimen of PrEP.72 Nevertheless, consistent
use is essential for the intervention to be effective. Notably,
none of these trials included women under age 18 years. Data
from the ongoing CHAMPS (“Pluspills”) study, which is the
first adolescent PrEP study to be conducted in adolescent
females globally, therefore will provide valuable information
on the feasibility, acceptability, and use of oral PrEP in this
vulnerable age group.73
Notwithstanding these challenges, the World Health
Organization (WHO) released guidelines in 2015 on the use
of oral PrEP containing tenofovir for HIV prevention to all
populations at high risk of acquiring HIV and as part of
combination prevention interventions.74 Several countries—
including France, Kenya, South Africa, and the United States
—have approved the use of oral tenofovir in combination
with emtricitabine PrEP formulations for HIV prevention.
The challenges are now to determine how best to implement
PrEP services in populations that would benefit most and
support high levels of adherence. Several combination HIV
prevention and demonstration projects of oral PrEP have been
initiated throughout the world to inform scale-up of PrEP in
populations such as young women.
HIV Prevention Interventions to Address
Structural Drivers of HIV
The use of microfinance, cash transfers, contingency
management, and behavioral economics is a novel strategy
being evaluated in several settings to incentivize safer HIV
risk behaviors, particularly in settings where poverty, gender
inequality, high school dropout rates, and other human rights
violations are key drivers in HIV risk-taking.75 The use of
contingency management has been successful in smoking
cessation, adherence in substitution therapy, keeping girls in
school, improving reproductive health outcomes, and enhanc-
ing childhood immunization coverage.76–80 The impact of
cash transfers on reducing risky sexual behavior and HIV
infection is mixed: some studies report reductions in risky
sexual behavior among adolescents, such as delaying sexual
debut, increasing condom use, and increasing retention in
school.81 In South Africa, an assessment of a publically
funded social grant program found that cash transfers were
associated with a 51% decrease in transactional sex and
a 71% reduction in age-disparate sex among girls, but that
they had no impact among boys.82 A cluster randomized
controlled trial in Malawi of cash incentives for school
attendance resulted in lower HIV prevalence at 18 months
in the intervention communities.83
However, 2 randomized controlled trials that assessed
the impact of cash transfers on HIV incidence showed no
impact. The HPTN 068 Swa Koteka study (n = 2448),
which provided cash incentives for school attendance,
found that there was no difference in HIV acquisition rates
between the young women who received the cash transfer
and those who did not.84 The CAPRISA 007 cluster
randomized controlled trial, which involved 3217 consent-
ing male (n = 1517) and female (n = 1700) students in
grades 9/10 in 14 schools in rural KwaZulu-Natal, showed
that conditional cash incentives for meeting any combina-
tion of 4 conditionalities (annual HIV testing, school
performance, participation in an HIV prevention program,
and participation in a community project) was associated
with a 30% reduction in HSV-2 incidence, but the trial did
not have sufficient statistical power to demonstrate an
impact on HIV incidence rates.85
The use of contingency management for HIV pre-
vention would need to carefully consider the desired behav-
iors that need to be changed and the feasibility and
desirability thereof in relation to the outcome. Regardless of
age, risk factors and context, HIV prevention is challenging,
with no quick fixes or one-size-fits-all solutions.
Integrating HIV Prevention Efforts With
Sexual and Reproductive Health Services
Early sexual debut, high teenage pregnancy rates, and
high school dropout rates are more common among adoles-
cent girls and young women from poorer socioeconomic
settings than they are among those from wealthier settings.
Not only is a woman’s risk of acquiring HIV increased in
high HIV burden settings, but there also is a high probability
of transmission to infants, particularly if there are delays in
seeking care and treatment. Information on sexual and
reproductive health that includes information about HIV
prevention is crucial from a young age. Schools are an
important venue for information dissemination and support
for young girls to complete high school and remain free from
HIV, STIs, and pregnancy.
In addition, access to adolescent-friendly sexual and
reproductive health services—including contraceptive choice,
safe abortions, and antenatal care—is particularly important
for the prevention of unintended pregnancies and maternal
deaths.35 Integration of these services with HIV prevention
efforts is an opportunity to reduce the obstacles between
adolescent girls and young women and the information,
support, and services they require. The Family Planning
Association in Malawi for example has successfully intro-
duced mobile clinics offering services for sexual and
reproductive health and HIV testing in rural areas. These
mobile education services can vastly increase the number of
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adolescent girls and young women who can obtain sexual
health knowledge and services.86
Societal norms that place a high value on young women
and men assuming more responsibility for their sexual
behavior and that do not tolerate gender-based violence or
older men having sex with teenagers are equally important to
ensuring adolescent girls and young women are able to grow
up in a safe environment and reach their full potential without
bearing children as children or acquiring HIV and other STIs.
Lessons from the PMTCT program in Malawi have shown
that, when the male partner is involved in the process—from
initial testing, to PMTCT, and through to the confirmation of
HIV status—adherence and uptake rates are significantly
higher.87 Greater male involvement increases uptake of
PMTCT, acceptance of HIV-positive status, use of fertility
control, and adherence to antiretroviral therapy (if infected); it
also results in a gradual positive attitude shift toward
prevention and reduces the rate of pediatric infections.88 In
contrast, unsupportive male partners have been associated
with poor communication between partners and higher rates
of intimate partner violence, abandonment, and discrimina-
tion once a woman reveals her positive HIV status.89
NEW HOPE IN PREVENTING HIV IN ADOLES-
CENT GIRLS AND YOUNG WOMEN
UNAIDS estimates that the number of new HIV
infections in the overall population in sub-Saharan Africa
declined by about 46% between 2000 and 2015, and by 37%
in young people.6 Although promising, these declines are too
small and too slow to alter the vulnerability of adolescent girls
and young women. After years of neglect, a global conver-
gence is emerging around the urgency to address the multiple
factors driving the HIV epidemic in adolescent girls and
young women.90
PEPFAR’s DREAMS (Determined, Resilient, Empow-
ered, AIDS-free, Mentored, and Safe) initiative, which was
launched on World AIDS Day in 2014, brings new hope for
meeting the prevention needs of adolescent girls and young
women and for creating an environment that supports them.
DREAMS is a public–private partnership that aims to reduce
HIV infections among adolescent girls and young women in
the 10 countries in sub-Saharan Africa that account for nearly
half of all new HIV infections. This is the first time in the
history of the HIV epidemic that a concerted advocacy and
programmatic effort is being made with substantial funding to
address the problem through a multipronged approach that
includes national campaigns, access to combination pre-
vention, the engagement of men (eg, linkage to HIV testing
and counseling, treatment and voluntary medical male
circumcision), integration of HIV services into sexual and
reproductive services, and efforts to keep girls in school.
The goal of DREAMS is to ensure that adolescent girls
and young women have access to prevention technologies
and strategies, and the opportunity to complete high school
and graduate HIV-negative, STI-free, and without pregnan-
cies. This will be accomplished using a combination of
available evidence and best practices (Fig. 1). It addresses
gender-based violence, young women’s rights, and the
creation of supportive communities that address the structural
drivers that directly and indirectly increase HIV risk among
girls (including poverty, gender inequality, sexual violence,
abbreviated schooling, and poor access to treatment for those
already infected with HIV). The inclusion of oral PrEP in the
DREAMS prevention package enhances access to a novel
HIV prevention option for young women. Together, these
efforts could help sustain the gains made to date and address
some of the key gaps and challenges that persist after the end
of the Global Plan by focusing on the most vulnerable group.
FIGURE 1. DREAMS package: best practices for preventing
HIV infection in adolescent girls and young women. Source:
DREAMS Innovation Challenge Fact Sheet: https://www.
pepfar.gov/documents/organization/247602.pdf. Used with
permission from Office of the U.S. Global AIDS Coordinator
and Health Diplomacy.
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Although focusing on adolescent girls and young
women is an important strategy to reduce the number of
new infections, unplanned pregnancies, and premature mater-
nal deaths; given the gender power disparities that underlie
the vulnerability of adolescent girls and young women,
inclusion of their male sexual partners in sexual and
reproductive health information sessions and access to HIV
prevention and treatment services could substantially enhance
the effectiveness of these initiatives. The role of community
and supportive environments to keep young girls in schools
and reduce teenage pregnancies and HIV is equally important.
The inclusion of both these aspects in the DREAMS initiative
makes the intervention even more powerful.
CONCLUSIONS
To date, there have been limited concerted efforts to
focus on or address the health needs of adolescents and young
people, as they are assumed to be healthy and not in need of
preventive, promotive, or therapeutic services. The “youth
bulge” in sub-Saharan Africa—and the notably dispropor-
tionate burden of HIV infection, premature loss of life, and
unmet sexual and reproductive health needs among adoles-
cent girls and young women—and the convergence of
communicable and noncommunicable diseases highlight this
important gap that requires urgent attention if we are to bridge
and reduce gender disparities. The gender divergence in HIV
acquisition and AIDS-related survival mirror where the
foundations for gender disparities and outcomes have been
laid. These age and sex differences in HIV infection place
young women in developing countries at substantial disad-
vantage that widens with age and has ramifications beyond
health. Preventing HIV infection in adolescent girls and
young women not only benefits this vulnerable population,
but it is critical to altering the current epidemic trajectories
and enabling epidemic control in eastern and southern Africa,
while sustaining the achievements of the Global Plan.
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